Palvella Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Palvella Therapeutics, Inc. (PVLA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.73 million shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2024-03-29
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2015-06-30 was 72.23K shares.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2015-03-31 was 25.00K shares.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 3.73M shares, a 21.22% increase from fiscal 2022.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 3.08M shares, a 3.37% decline from fiscal 2021.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2021 was 3.18M shares, a 37.69% increase from fiscal 2020.
- Palvella Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2020 was 2.31M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|
| 2023-12-31 | 3.73M shares 10-K · filed 2024-03-29 | ||
| 2022-12-31 | 3.08M shares 10-K · filed 2024-03-29 | ||
| 2021-12-31 | 3.18M shares 10-K · filed 2023-03-31 | ||
| 2020-12-31 | 2.31M shares 10-K · filed 2022-03-02 | ||
| 2015-12-31 | 305.33K shares 10-K · filed 2016-03-23 | ||
| 2015-06-30 | 72.23K shares 10-Q · filed 2015-08-13 | 97.23K shares derived: sum of 2 quarters · filed 2015-08-13 | |
| 2015-03-31 | 25.00K shares 10-Q · filed 2015-08-13 | ||
| 2014-12-31 | 2.52M shares 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |